AARDEX Group is dedicated to staying at the forefront of industry knowledge and expertise. That's why we regularly attend industry events and host webinars featuring top-tier experts in medication adherence. These webinars provide valuable insights and give attendees a front-row seat to the latest industry trends and developments.
LEARN WITH AARDEX GROUP
We are excited to offer on-demand and upcoming webinars focused on medication adherence. Our webinars feature industry-leading experts who provide actionable insights and strategies to improve medication adherence and ultimately, patient outcomes. Whether you are a healthcare provider, researcher, or patient, our webinars offer invaluable information and resources to help you better understand medication adherence and its importance in healthcare. Don't miss out on this opportunity to learn from the best in the field and stay up-to-date on the latest advancements in medication adherence. Register now for our upcoming webinars or access our on-demand webinars at any time.
Rebecca Beck, BD, Bernard Vrijens, AARDEX Group, and Arnaud Guillet, Biocorp
Job Van Boven, Associate Professor, University Medical Center Groningen, and Bernard Vrijens, Scientific Lead, AARDEX Group
Matt Bolton of Merck and Ning Yu of Biogen
Ken Kaitin, TUFTS, John Musaus, Thermo Fisher and Timothy Peters-Strickland, PPD
WHERE TO FIND US NEXT
Our medication adherence experts are on a mission to change the game in clinical trials. They'll be taking our message to the people at several upcoming conferences. If you're ready to join the movement and revolutionize your approach to adherence in clinical trials, be sure to catch us at one of these events.
June 26-28, 2024, Tokyo, Japan
July 8, 2024, 6:30-8:30pm, Boston Mariott Burlington, USA
July 9-10, 2024, Boston, USA
August 30, 2024, Brussels, Belgium
November 10-13, 2024, Boston, USA
November 21-23, 2024, Naples, Italy
IN CONVERSATION WITH MERCK & BIOGEN
Mitigating the Risk of Poor Adherence in Trials
Watch this live recording with adherence experts from Merck & Biogen to learn about their approach to mitigating the risk of poor adherence in trials.
FROM THE AARDEX GROUP BLOG
We are thrilled to feature expert insights from Bernard Vrijens, a world-renowned expert on medication adherence. Taking medication as prescribed is crucial to achieving optimal health outcomes, yet non-adherence is a prevalent issue. Bernard Vrijens' extensive research and experience in the field provide invaluable insights into the factors that contribute to medication non-adherence and effective strategies to address them. His contributions to our medication adherence blog offer actionable advice and evidence-based recommendations to improve medication adherence and ultimately, patient outcomes.
Liège, Belgium and Gothenburg, Sweden – October 15, 2024: AARDEX Group, a leader in managing drug exposure in clinical trials, and precision medicine innovators, and OnDosis, a game changer in precision dosing of oral solid medicines through the novel Dosage
In recent years, the pharmaceutical industry has borne witness to the meteoric rise of glucagon-like peptide-1 receptor agonist (GLP-1) therapies. Having fast become established as a potentially life-changing treatment for Type 2 diabetes and obesity, emerging evidence of the cardio and
Let us first recognise the enormity of the challenges we are facing, on a global scale, when it comes to cancer. It is estimated that there were 18.1 million new cases of cancer worldwide in 2020, with around 10 million
AARDEX Group, the global leader in medication adherence solutions, has today announced a collaboration agreement with Compliance Meds Technologies (CMT), a mobile-health technology solutions provider. In this cooperation, the partners will combine the AARDEX MEMS® Adherence Software with CMT’s CleverCap®
Medication adherence is a vital component in managing chronic diseases effectively. However, it remains a significant challenge, with non-adherence rates reaching up to 50% among patients. This lack of adherence results in poor health outcomes and increased burdens on healthcare
In a recent paper titled ‘The impacts of undetected nonadherence in phase II, III and post-marketing clinical trials: An overview’ the authors detailed the findings of a research project which aimed to provide an overview of the consequences of unrecognized